Media headlines about Sientra (NASDAQ:SIEN) have trended positive on Friday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sientra earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 47.9274147608834 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Global Breast Implants Market by 2023: GC Aesthetics, Silimed (Sientra), Mentor Worldwide and Allergan (thetechnicalprogress.com)
- Sientra (NASDAQ:SIEN) Institutional Investors Sentiment Index Increased in 2017 Q4 (nmsuherald.com)
- Factors of Influence in 2018, Key Indicators and Opportunity within Sientra, Primo Water, Andeavor Logistics LP, RE … (menafn.com)
- Sientra Reports the Long-term Safety and Effectiveness of Silicone Gel Breast Implants with Results from the Largest … (prnewswire.com)
- Head-To-Head Comparison: Histogenics (HSGX) & Sientra (SIEN) (americanbankingnews.com)
Sientra stock opened at $9.35 on Friday. The company has a market cap of $181.90, a price-to-earnings ratio of -3.32 and a beta of -1.06. Sientra has a 52-week low of $7.20 and a 52-week high of $16.68.
Several research firms have recently issued reports on SIEN. Maxim Group began coverage on Sientra in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 price objective for the company. Zacks Investment Research downgraded Sientra from a “buy” rating to a “hold” rating in a research note on Saturday, March 17th. ValuEngine raised Sientra from a “sell” rating to a “hold” rating in a research note on Saturday, March 17th. Canaccord Genuity decreased their target price on shares of Sientra from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 14th. Finally, William Blair reissued a “buy” rating on shares of Sientra in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.50.
WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/sientra-sien-getting-favorable-press-coverage-study-shows/2029458.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.